For research use only. Not for therapeutic Use.
Bezafibrate（Cat No.:A000586）is a fibrate class medication used to manage dyslipidemia by lowering triglycerides and increasing high-density lipoprotein (HDL) cholesterol levels. It works by activating peroxisome proliferator-activated receptors (PPARs), which regulate lipid metabolism. Bezafibrate is effective in reducing the risk of cardiovascular events in patients with mixed hyperlipidemia and hypertriglyceridemia. It also has beneficial effects on glucose metabolism, making it useful for patients with metabolic syndrome. Common side effects include gastrointestinal disturbances and mild liver enzyme elevations. Bezafibrate’s lipid-modifying properties make it a valuable tool in cardiovascular risk management.
| Catalog Number | A000586 |
| CAS Number | 41859-67-0 |
| Synonyms | 41859-67-0; Bezalip; Cedur; Befizal; Bezafibrat |
| Molecular Formula | C19H20ClNO4 |
| Purity | ≥95% |
| Target | PPARα Agonist |
| Storage | -20°C |
| IUPAC Name | 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid |
| InChI | InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24) |
| InChIKey | IIBYAHWJQTYFKB-UHFFFAOYSA-N |
| SMILES | CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl |
